Recent

% | $
Quotes you view appear here for quick access.

HSBC Holdings plc Message Board

markedtofuture 7 posts  |  Last Activity: Jul 2, 2016 11:10 AM Member since: May 25, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Yahoo sensors in action about....

    Bill Gates is proud to announce that Microsoft has partnered with KIND Financial to provide a seed-to-sale tracking system. The partnership will create ATM-like kiosks and a way for cannabis collectives to deal in cash without risking their lives.

  • Tuesday June 7, 2016 by Jason Napodano

    Last week, shares of Immune Pharmaceuticals (IMNP) spiked in response to Jazz Pharma's acquisition of Celator Pharma for $1.5 billion. Celator is developing VYXEOS™, a liposome injection of cytarabine +
    daunorubicin for patients with high-risk (secondary) acute myeloid leukemia (AML). Back in March 2016, Celator announced Phase 3 data showing its formulation to be vastly superior to the standard of care regimen of cytarabine + daunorubicin, known as "7+3". In my opinion, VYXEOS will become the new standard of care for induction therapy in patients with high-risk AML. Jazz's take-out of Celator at nearly 100% premium has brought significant investor interest to the AML space.

    Over the past few months, Immune has been highlighting new analyses of data with Ceplene® hinting at a potential path forward for the drug. Ceplene (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2) for maintenance of remission in patients with AML following successful induction therapy. In theory, these are patients (or future patients) that achieve complete remission (CR) using VYXEOS but are ineligible for a "curative" bone marrow transplant (BMT) or still considered high-risk for relapse post-consolidation or post-BMT.

    Investors briefly turned their enthusiasm for AML stocks to Immune early last week. Whether or not the spike in Immune Pharma shares was warranted is the subject of an article on Seeking-Alpha by Tom Mathies (see article). In short, the author does not believe Ceplene has a viable future. However, I've studied some of the recent data that Immune has presented, including a new post hoc analysis from the Phase 3 trial and new data biomarker response analysis presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2016, and I think there are some key points worth mentioning about Immune's Ceplene strategy.

    Continued...

  • June 3, 2016 6:49 AM EDT

    FBR Capital analyst, Vernon Bernardino, thinks that Immune Pharmaceuticals (NASDAQ: IMNP) is currently undervalued when considering the collective value of its clinical-stage assets. Following Jazz Pharmaceuticals' (JAZZ) recent announcement of its $1.5B acquisition of Celator Pharmaceuticals (CPXX) for Vyxeos, the latter's Phase III stage product candidate for acute myeloid leukemia (AML). The analyst thinks Ceplene, an IMNP asset already approved in the EU and Israel as a treatment for maintenance of complete response (CR) in patients with AML, alone is undervalued.

    No change to Outperform rating or $3 PT.

    streetinsider

  • Glenn Grissom June 02, 2016

    Immune Pharmaceuticals, Inc. (NASDAQ:IMNP)

    Last Trade: The Company closed its last session at $0.4 with the gain of 21.21%. The market capitalization of the company is $13.51 Million, with the average Volume of 298.73K. The stock currently has its 52-Week High range of $2.23 and 52-week low range of $0.2. The Price to Sales (P/S) of the company is 0 whereas, P/B (Price to Book) stands at 2.54. By looking at the Volatility of the company, Week Volatility is at 27.69% and Month Volatility is at 17.69%.

    For the current Fiscal Quarter, 2 analysts have given an Average earnings estimate of -$0.13 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is -$0.14 whereas, High Estimate is -$0.12. The Previous Year EPS of this Quarter is -$0.12.

    Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) currently has High Price Target of $3. The Low and Mean Price Targets are $1 and $2 respectively. These price targets are a consensus analysis of 2 brokers.

    When having a look at Recommendation Trends of the stock polled by Thomson First call. For the Current month, 1 analysts have assigned this stock as Strong Buy where 2 assigned Buy, 0 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.

    beaconchronicle

  • markedtofuture markedtofuture Jun 2, 2016 10:55 AM Flag

    Google- Novel Pain Therapeutics LLC, Immune Pharmaceuticals, Inc.

    4th link down - License Option Agreement - SEC gov

    It is the address of the new LLC that was formed. The monied interests are doing their thing.

    If to Immune: Immune Pharmaceuticals Inc.
    430 East 29th Street, Suite 940
    New York, NY 10016
    Attn.: Daniel Teper, CEO

    If to NPT : Novel Pain Pharmaceuticals LLC
    c/o 52 East End Avenue #12A
    New York, NY 10028
    Attn.: Mark S. Fawer


    It looks like the gap at .34 should get filled... retracing on low volume.

  • markedtofuture markedtofuture Jun 1, 2016 4:48 PM Flag

    Novel Pain Therapeutics LLC, Immune Pharmaceuticals, Inc.

    This Agreement made this day of May 15, 2016 by and between Immune Pharmaceuticals Inc. (“Immune”) with a principal place of business at 430 East 29th Street, Suite 940, New York, NY 10016 and Novel Pain Therapeutics LLC (“NPT”), a newly formed limited liability company with an office at 52 East End Avenue #12A New York, NY 10028

    See License Option Agreement - SEC gov

  • Shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) are finally bouncing after being on a downtrend all year. Bottom fishers are waking up to the fact that Immune is a cheap lotto ticket at current levels. We look at IMNP as a great risk/reward play with the upside potentially being several times your money. That’s why it’s a worthwhile look at these levels.

    Immune Pharmaceuticals describes itself as “a clinical stage biopharmaceutical company specializing in the development and commercialization of novel targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The company focuses on a precision medicine approach to treatment of diseases by incorporating methods for better patient selection in its clinical trials and the potential for development of companion diagnostics. The company’s immuno-inflammation product pipeline includes: bertilimumab, a clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation, a portfolio of clinical-stage immune oncology products and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis.”

    The highlight of the recent update was that IMNP executed an exclusive 60-day option with Novel Pain Therapeutics (“NPT”) to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.

    Continued.....insider financial Wednesday, 01 Jun 2016 08:08 AM

HSBC
37.20+0.63(+1.72%)Aug 31 4:02 PMEDT